Clinical Trials
37 trialsNCT02158858 2026-06-04
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Constellation Pharmaceuticals
Phase 1/2 Completed
NCT04339400 2026-06-03
A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT07612280 2026-06-03
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis
Jubilant Therapeutics Inc.
Phase 1/2 Recruiting
NCT07441694 2026-05-29
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
NCT07469891 2026-05-29
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Prelude Therapeutics
Phase 1 Recruiting
NCT04064060 2026-05-28
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Celgene
Phase 3 Recruiting
NCT05456191 2026-05-27
ASC4START
Novartis
Phase 3 Active not recruiting
NCT05320198 2026-05-13
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Disc Medicine, Inc
Phase 1/2 Recruiting
NCT04877522 2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4 Recruiting
NCT04996875 2026-05-05
APEX
Cogent Biosciences, Inc.
Phase 2 Recruiting
NCT06313593 2026-05-04
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
NCT06034002 2026-04-17
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
NCT04562389 2026-04-09
SENTRY
Karyopharm Therapeutics Inc
Phase 3 Active not recruiting
NCT07008118 2026-04-06
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
NCT04279847 2026-04-01
LIMBER
Incyte Corporation
Phase 1 Active not recruiting
NCT05936359 2026-03-24
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
NCT02467270 2026-03-17
OPTIC
Takeda
Phase 2 Completed
NCT06743035 2026-01-09
ROPE
iOMEDICO AG
Recruiting
NCT04509700 2025-12-10
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Incyte Corporation
Phase 2 Active not recruiting
NCT04576156 2025-12-04
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Geron Corporation
Phase 3 Active not recruiting
NCT03011372 2025-11-18
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Incyte Corporation
Phase 2 Completed
NCT00726232 2025-10-29
Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia
Incyte Corporation
Phase 2 Terminated
NCT03452774 2025-10-28
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Recruiting
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT04551066 2025-10-21
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Incyte Corporation
Phase 3 Terminated
NCT04551053 2025-10-02
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
Incyte Corporation
Phase 3 Terminated
NCT05153343 2025-10-01
Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1/2 Completed
NCT04182100 2025-09-15
Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply
PharmaEssentia Japan K.K.
Phase 2 Completed
NCT04629508 2025-09-02
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
Incyte Corporation
Phase 2 Completed
NCT03952039 2025-08-28
FREEDOM2
Celgene
Phase 3 Completed
NCT04285086 2025-08-13
SURPASS ET
PharmaEssentia
Phase 3 Active not recruiting
NCT05482971 2025-08-13
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
PharmaEssentia
Phase 2 Active not recruiting
NCT06468033 2025-08-13
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
PharmaEssentia
Phase 3 Recruiting
NCT06290765 2025-07-31
PV
PharmaEssentia
Phase 4 Not yet recruiting
NCT05444530 2025-07-20
A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
Janssen Research & Development, LLC
Phase 1 Completed
NCT04717414 2025-07-10
INDEPENDENCE
Celgene
Phase 3 Active not recruiting
NCT04603001 2025-06-27
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting